DiaMedica Therapeutics Inc.
DMAC
Rank in Stocks
#11874
DiaMedica Therapeutics Inc. operates as a clinical-stage biopharmaceutical... DiaMedica Therapeutics Inc. operates as a clinical-stage biopharmaceutical entity dedicated to advancing therapeutic solutions for neurological and renal disorders. Its primary drug candidate, DM199, a recombinant human tissue kallikrein-1 protein, is currently undergoing a Phase 2 REDUX trial to assess its efficacy in treating moderate to severe chronic kidney disease linked to Type 1 or Type 2 diabetes. Furthermore, DM199 is being evaluated in Phase 2/3 REMEDY2 trials for acute ischemic stroke patients. In addition to DM199, the company is also developing DM300, which is in its pre-clinical stage for the treatment of various inflammatory conditions. Founded in 2000 and headquartered in Minneapolis, Minnesota, the company was previously known as DiaMedica Inc. before adopting its current name, DiaMedica Therapeutics Inc., in December 2016.
Share Price
$9.65
Last synced: 2026-11-09
Market Cap
$520.38M
Change (1 day)
3.10%
Change (1 year)
51.02%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade DiaMedica Therapeutics Inc. (DMAC)
Category
Healthcare
EPS for DiaMedica Therapeutics Inc. (DMAC)
EPS as of June 2026 TTM: $-0.72
According to DiaMedica Therapeutics Inc.'s latest financial reports, its current EPS (TTM) is $-0.72. At the end of 2025 the company had an EPS of $-0.70, a decrease compared to its 2024 EPS of $-0.60.
EPS history for DiaMedica Therapeutics Inc. from 2004 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-0.72 | 2.86% |
| 2025 | $-0.70 | 16.67% |
| 2024 | $-0.60 | 0.00% |
| 2023 | $-0.60 | 15.38% |
| 2022 | $-0.52 | -20.00% |
| 2021 | $-0.65 | -16.67% |
| 2020 | $-0.78 | -12.36% |
| 2019 | $-0.89 | 20.27% |
| 2018 | $-0.74 | 2.78% |
| 2017 | $-0.72 | 53.19% |
| 2016 | $-0.47 | 17.50% |
| 2015 | $-0.40 | -74.19% |
| 2014 | $-1.55 | -42.80% |
| 2013 | $-2.71 | -34.06% |
| 2012 | $-4.11 | 40.27% |
| 2011 | $-2.93 | -1.68% |
| 2010 | $-2.98 | 17.32% |
| 2009 | $-2.54 | 24.51% |
| 2008 | $-2.04 | -29.90% |
| 2007 | $-2.91 | 226.97% |
| 2006 | $-0.89 | 270.83% |
| 2005 | $-0.24 | 921.28% |
| 2004 | $-0.02 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | -2,275.00% |
US
|
|
| $-7.07 | 881.94% |
US
|
|
| $-5.29 | 634.72% |
AU
|
|
| $12.88 | -1,888.90% |
BE
|
|
| $21.56 | -3,094.44% |
NL
|
Questions about DiaMedica Therapeutics Inc.'s earnings per share (EPS)
What is DiaMedica Therapeutics Inc.'s earnings per share (EPS)?
DiaMedica Therapeutics Inc.'s earnings per share (EPS) over the last twelve months is $-0.72, as of Jun 2026.
What was DiaMedica Therapeutics Inc.'s earnings per share (EPS) in 2025?
In 2025, DiaMedica Therapeutics Inc.'s earnings per share (EPS) was $-0.70, compared with $-0.60 in 2024.
How has DiaMedica Therapeutics Inc.'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, DiaMedica Therapeutics Inc.'s earnings per share (EPS) was highest in 2022 ($-0.52) and lowest in 2020 ($-0.78).
How does DiaMedica Therapeutics Inc.'s earnings per share (EPS) compare with similar companies?
DiaMedica Therapeutics Inc.'s earnings per share (EPS) ($-0.72) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.